We are thrilled to announce that we received a global award for exception achievement from the international awards program The Global Recognition Awards™. We couldn’t be prouder of our team and the countless hours they’ve put into revolutionizing cancer diagnostics and digital pathology by raising the standard for tissue quality with our software and pre-analytical tech. We also want to thank our users and partners who’ve helped us realize the dreams of our founders to provide better patient care worldwide, especially in under served, remote areas.
What the judging panel said:
Our independent judging panel has awarded you a Global Recognition Award for exceptional achievement.
The selection process is highly competitive. Of the 15,000 entrants each year, only 5.8% of applicants receive recognition, making your achievement significant. You are in exceptional company.
What have I won?
Lumea (Leavitt Medical Inc. dba Lumea) has been recognized with a 2026 Global Recognition Award for transforming the pre-analytical phase of prostate cancer diagnostics through a fully integrated, patent-protected ecosystem that has delivered measurable improvements in specimen quality, molecular testing access, and diagnostic accuracy across more than 130 clinical sites worldwide, earning this distinction in the category of Innovation.
Prostate cancer is the most commonly diagnosed malignancy in men worldwide, yet the most consequential step in its diagnosis, the handling of tissue from needle to pathologist, had gone unengineered for decades. Lumea identified this critical gap and built a solution grounded in physical first principles, addressing what had long been treated as an unavoidable limitation of the diagnostic process. The pre-analytical phase, defined as the interval between tissue extraction and completion of fixation, accounts for up to 92.9% of all laboratory non-conformities in histopathology, and no purpose-built commercial solution existed before Lumea entered the field.
Traditional specimen handling introduces a cascade of preventable errors, because dropping a needle core biopsy into a formalin bottle causes fluid turbulence, fragmentation, and unconstrained coiling that distort the tissue before a pathologist ever examines it. Submitting multiple cores in a single container triples the fragmentation rate from 14% to 41%, and these artifacts introduce variability into Gleason grading, generate equivocal diagnoses that trigger unnecessary repeat biopsies, and degrade the molecular profiling samples required for precise cancer management. Lumea’s research identified a clinically striking paradox, since the most aggressive, high-grade tumors that most urgently require precise grading are also the most physically fragile, meaning traditional workflows fail most severely at exactly the moment diagnostic precision matters most.
Engineering a New Standard
Lumea’s response to this systemic failure is a fully integrated pre-analytical and digital pathology ecosystem, which carries FDA clearance or approval across four products and CE marking for BxBoard, BxChip, and Viewer+ in European markets. The BxBoard’s 0.35 mm narrow lanes provide lateral mechanical support from the moment of extraction, while a hydrophilic sponge delivers accelerated, even fixation through capillary action, a vapor-phase method that was validated using time-lapse photography of standardized porcine tissue explants. This approach maintains tissue geometry, prevents coiling, and eliminates the mechanical distortion associated with formalin bottle transport, representing a fundamental shift from passive specimen containment to active, engineered tissue preservation.
The BxChip receives specimens at the laboratory in a tissue-mimetic matrix, enforcing standardized orientation through processing and embedding, while BxCamera brings standardized gross photography to the laboratory grossing station, creating a documented visual record of specimen receipt. Viewer+ connects specimen data, laboratory information management, and AI-ready digital slide viewing into a unified workflow, and it is deployed commercially across Europe through Lumea’s international distributor network. The entire ecosystem is protected by six granted U.S. patents covering tissue cassette architecture, cytological sample preparation, on-site biopsy management systems, tissue sample management network architecture, and two design patents, reflecting the depth of engineering investment behind what can appear, on the surface, to be a simple consumable.
Evidence at Scale
Lumea’s clinical evidence is exceptional in scope and rigor for a company of its size, with a comparative study of 2,812 prostate needle core biopsies showing a statistically significant 35% reduction in core fragmentation, with mean breakpoints per core falling from 2.0 to 1.3. A Bayesian meta-analysis, evaluated using the Rasch model to create a linear measurement scale that enabled precise comparisons across 130 clinical sites, demonstrated a 28% increase in evaluable core length, representing a mean gain of 3.62 mm per core. That gain aggregates to over 43 mm of additional diagnostic material in a standard 12-core protocol, and core length exceeding 11.9 mm is independently associated with a 2.57-fold higher likelihood of cancer detection, making every preserved millimeter a direct reduction in diagnostic ambiguity.
A retrospective review of 28,309 single needle core biopsies confirmed consistent fixation quality across independently reviewed slides, providing real-world validation at a scale rarely seen in pre-analytical research. BxBoard-processed specimens are 2.1 times less likely to result in test cancellation due to insufficient quantity or RNA degradation, 0.59% versus 1.27%, ensuring patients can access genomic risk stratification without requiring repeat tissue sampling. The system also reduces total laboratory processing time by 76% and embedding time by 83%, delivering meaningful throughput gains in high-volume urology practices while simultaneously advancing the clinical equity goals that underpin precision medicine.
Lumea’s published research has been cited in the Journal of Urology, American Journal of Clinical Pathology, Modern Pathology, and BJUI Compass, reflecting reach across anatomical pathology, biomedical engineering, molecular oncology, and AI-assisted diagnostics. The 35% fragmentation reduction that Lumea achieves directly improves input quality for computational grading algorithms, since fragmented cores introduce edge artifacts that degrade AI performance at the analytical stage. The company has been recognized by the American Urological Association and KLAS, and its distributor network covers 14 countries across Western Europe, Eastern Europe, Scandinavia, and the Middle East, underscoring the global relevance of its pre-analytical platform.
Final Words
Lumea identified a failure mode the entire field had accepted as inevitable and engineered a solution that is now deployed across more than 130 clinical sites, supported by multi-market regulatory clearance and a substantial patent portfolio. Its pre-analytical system directly improves the input quality that AI grading algorithms require, positioning the company at the intersection of specimen science and computational medicine, where standardization of upstream processes determines the reliability of downstream diagnostics. The 35% fragmentation reduction Lumea achieves is not an incremental gain, but a structural shift in what the prostate cancer diagnostic pathway can reliably deliver for patients and clinicians alike.
The pre-analytical phase is where the promise of precision medicine is either preserved or lost, and Lumea has made it the most protected and rigorously validated step in the entire workflow. Its work covers genomics, digital pathology, AI readiness, and clinical equity, making this recognition a reflection of demonstrated, measurable impact across multiple disciplines. Alex Sterling, a spokesperson for Global Recognition Awards, stated, “Lumea exemplifies what this award exists to recognize: a company that did not accept an entrenched problem as inevitable, but instead engineered its way to a solution that is now improving diagnostic outcomes for patients around the world.”
What This Means:
Your application was evaluated by impartial industry experts using the Rasch measurement model, which is a rigorous methodology that creates objective scoring regardless of category or field. Only the highest-performing applicants receive this recognition.
About Lumea
Lumea is a healthcare technology company redefining cancer diagnostics through specialty-integrated workflows purpose-built to transform the diagnostic journey. By reimagining the workflow rather than simply digitizing it, Lumea supports 40% of the U.S. outpatient prostate market and delivers a proven 18.79% increase in cancer detection rates, with national leadership in primary digital diagnostics across gastroenterology and dermatology. This specialty-driven approach prioritizes the people behind every diagnosis, positioning Lumea as the core system guiding critical treatment decisions when they matter most.
About The Global Recognition Awards™
Global Recognition Awards is an international awards program that recognizes companies, leaders, and organizations demonstrating exceptional achievement across business, leadership, innovation, service, and related performance categories. Applications are evaluated by impartial industry experts using a rigorous scoring methodology designed to support fair and objective assessment across industries. For more information about GRA Awards, visit www.globalrecognitionawards.org.
